Login
$NEUP
$2.52 +$0.04 (1.43%) After hours

$NEUP 8-K SEC Filings

Filed On Filing
23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders

This Amendment No. 1, dated as of October 23, 2026 (this “Amendment”), amends that certain Rights Agreement, dated as of October 27, 2025 (the “Rights Agreement”), by and between Neuphoria Therapeutics Inc., a Delaware corporation (the “...

24 Jul 2026 8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +1 more

This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of July 23, 2026, is entered into by and among Scancell Holdings plc, a public limited company incorporated under the laws of England and Wales (“Parent”), Scancell Merger Su...

26 May 2026 8-K: Other Events

On May 21, 2026, Neuphoria Therapeutics Inc. (the “Company”) received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s l...

08 Jan 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

THIS INDEPENDENT CONTRACTOR AGREEMENT (“Agreement”) is effective as of January 1, 2026 (the “Effective Date”) by and between Neuphoria Therapeutics, Inc., a Delaware corporation (the “Company”), and Spyridon “Spyros” Papapetropoulos (“In...

18 Dec 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on July 18, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a deficiency notification letter (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”). The Notice i...

17 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 12, 2025, the Company held an Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the four proposals described below. The proposals presented at the Annual Meeting...

27 Oct 2025 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more

This Rights Agreement (this “Agreement”) is dated as of October 27, 2025 (the “Agreement Date”) and is made between Neuphoria Therapeutics Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally c...

20 Oct 2025 8-K: Other Events

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

16 Sep 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a deficiency notification letter (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”). The Notice in...

18 Jul 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 18, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a deficiency notification letter (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”). The Notice indicated that the Company...

20 May 2025 8-K: Results of Operations and Financial Condition

AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025

14 Jan 2025 8-K: Other Events

On January 10, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with Nasdaq Listing ...

23 Dec 2024 8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +7 more

Neuphoria Therapeutics Inc. (a company incorporated in Delaware)

16 Dec 2024 8-K: Other Events

Adelaide, Australia and Cambridge, Mass., December 16, 2024 (GLOBE NEWSWIRE) – Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has toda...

12 Dec 2024 8-K: Submission of Matters to a Vote of Security Holders

Adelaide, Australia and Cambridge, Mass., December 12, 2024 (GLOBE NEWSWIRE) – Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from...

21 Nov 2024 8-K: Entry into a Material Definitive Agreement

Bionomics Limited, a corporation organized under the laws of the Commonwealth of Australia (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:

08 Nov 2024 8-K: Other Events

for a scheme of arrangement in relation to the proposed acquisition by Neuphoria Therapeutics Inc. of the ordinary shares in Bionomics Limited (ACN 075 582 740).

10 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

On October 9, 2024, Mr. Aaron Weaver, a member of the Board of Directors of Bionomics Limited (the “Company”), provided the Company’s board with notice that he was resigning from the Board of Directors, effective October 9, 2024. Mr. Wea...

02 Oct 2024 8-K: Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (a company incorporated in Delaware)

16 Jul 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 11, 2024, Bionomics Limited (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s American Depositary...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support